NRx Pharmaceuticals Receives $4.3M FDA Waiver for NRX-100 Ketamine Therapy
NRx Pharmaceuticals announced a $4.3M FDA waiver for its NRX-100 ketamine therapy, signaling progress in treating suicidal depression. This development underscores the company's dedication to mental health innovation.
This news matters as it highlights NRx Pharmaceuticals' progress in developing a potentially groundbreaking therapy for suicidal depression. The FDA waiver signifies a significant step towards providing innovative treatment options for patients in need, showcasing the company's commitment to addressing mental health challenges.